Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
The global demand for next-generation metabolic treatments has sparked a fierce competition, forcing retail investors to decide between Eli Lilly & Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) for their long-term portfolios. Eli Lilly focuses on drug discovery and marketing across 90 countries, while Novo Nordisk leverages its Danish roots to lead in diabetes and rare disease therapies. Both companies are currently scaling their manufacturing capacity to meet soaring patient needs. This comparison clarifies which business model and valuation currently offer the more compelling opportunity through 2027. Eli Lilly develops and markets human pharmaceutical products in approximately 90 countries. In the U.S., the company relies on wholesale distributors like McKesson Corp. (NYSE:MCK) , Cencora Corp. (NYSE:COR) , and Cardinal Health (NYSE:CAH) , which each account for significant revenue. To expand access, it uses the LillyDirect platform and manages collaborations with partners like Innovent Biologics (OTC:IVBXF) . Continue reading